PL2420491T3 - 3,5-Podstawione piperydyny jako inhibitory reniny - Google Patents

3,5-Podstawione piperydyny jako inhibitory reniny

Info

Publication number
PL2420491T3
PL2420491T3 PL11185536T PL11185536T PL2420491T3 PL 2420491 T3 PL2420491 T3 PL 2420491T3 PL 11185536 T PL11185536 T PL 11185536T PL 11185536 T PL11185536 T PL 11185536T PL 2420491 T3 PL2420491 T3 PL 2420491T3
Authority
PL
Poland
Prior art keywords
piperidine compounds
renin inhibitors
substitued
substitued piperidine
renin
Prior art date
Application number
PL11185536T
Other languages
English (en)
Inventor
Takeru Ehara
Fumiaki Yokokawa
Philipp Grosche
Osamu Irie
Yuki Iwaki
Takanori Kanazawa
Shimpei Kawakami
Kazuhide Konishi
Muneto Mogi
Masaki Suzuki
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37875514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2420491(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0604223A external-priority patent/GB0604223D0/en
Priority claimed from GB0611390A external-priority patent/GB0611390D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2420491T3 publication Critical patent/PL2420491T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL11185536T 2005-12-30 2006-12-28 3,5-Podstawione piperydyny jako inhibitory reniny PL2420491T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05028771 2005-12-30
GB0604223A GB0604223D0 (en) 2006-03-02 2006-03-02 Organic compounds
GB0611390A GB0611390D0 (en) 2006-06-08 2006-06-08 Organic compounds
EP11185536.7A EP2420491B1 (en) 2005-12-30 2006-12-28 3 , 5-substitued piperidine compounds as renin inhibitors
EP06829892.6A EP1968940B1 (en) 2005-12-30 2006-12-28 3 , 5-substitued piperidine compounds as renin inhibitors

Publications (1)

Publication Number Publication Date
PL2420491T3 true PL2420491T3 (pl) 2013-12-31

Family

ID=37875514

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11185536T PL2420491T3 (pl) 2005-12-30 2006-12-28 3,5-Podstawione piperydyny jako inhibitory reniny

Country Status (20)

Country Link
US (1) US8129411B2 (pl)
EP (2) EP2420491B1 (pl)
JP (1) JP5306821B2 (pl)
KR (1) KR20080086921A (pl)
AR (1) AR058885A1 (pl)
AU (1) AU2006332124B2 (pl)
BR (1) BRPI0620736A2 (pl)
CA (1) CA2633624C (pl)
CR (1) CR10091A (pl)
EC (1) ECSP088587A (pl)
ES (2) ES2476422T3 (pl)
IL (1) IL192024A0 (pl)
MA (1) MA30073B1 (pl)
NO (1) NO20083315L (pl)
NZ (1) NZ569135A (pl)
PE (2) PE20110117A1 (pl)
PL (1) PL2420491T3 (pl)
PT (1) PT2420491E (pl)
TW (1) TW200738698A (pl)
WO (1) WO2007077005A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
JP5306821B2 (ja) 2005-12-30 2013-10-02 ノバルティス アーゲー レニン阻害剤としての３，５−置換ピペリジン化合物
EP2526948A1 (en) 2006-09-20 2012-11-28 Aerie Pharmaceuticals, Inc. RHO kinase inhibitors
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8129538B1 (en) 2007-03-28 2012-03-06 Takeda Pharmaceutical Company Limited Renin inhibitors
NZ582098A (en) 2007-06-25 2012-03-30 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
EP2202228B1 (en) 2007-10-15 2014-12-10 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
CA2708866A1 (en) 2007-12-19 2009-06-25 Hiroyuki Nakahira Bicyclic heterocyclic derivative
US8889714B2 (en) 2008-05-05 2014-11-18 Actelion Pharmaceuticals Ltd. 3,4-substituted piperidine derivatives as renin inhibitors
SG188117A1 (en) 2008-06-19 2013-03-28 Takeda Pharmaceutical Heterocyclic compound and use thereof
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP2421828A2 (en) * 2009-04-24 2012-02-29 Cadila Healthcare Limited Piperidine derivatives as inhibitors of renin
WO2010126626A2 (en) 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
KR20120109292A (ko) 2009-06-24 2012-10-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Ｎ-치환-시클릭 아미노 유도체
KR20140092696A (ko) * 2013-01-16 2014-07-24 주식회사유한양행 신규의 페닐에티닐 벤즈아마이드 글루코키나제 활성화제 및 그의 제조방법
ES2776199T3 (es) 2013-03-15 2020-07-29 Aerie Pharmaceuticals Inc Conjugados de compuestos de isoquinolina y prostaglandinas
EP3130581A4 (en) * 2014-04-10 2017-11-22 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2017086941A1 (en) * 2015-11-17 2017-05-26 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2018045091A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN117986146A (zh) * 2023-12-22 2024-05-07 河南优凯制药有限公司 一种枸橼酸喷托维林杂质的制备方法及其检测方法
CN119059970B (zh) * 2024-08-30 2026-03-24 上海信诺维生物医药有限公司 一种btk抑制剂药物中间体的制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224941B (pl) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
DE69212844T2 (de) 1991-12-18 1997-01-09 Schering Corp., Kenilworth, N.J. Imidazolyl oder imidazolylalkyl substituiert mit einem 4- oder 5-gliedrigen stickstoff enthaltenden heterozyklischen ring
IL111176A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
PL193686B1 (pl) * 1995-09-07 2007-03-30 Hoffmann La Roche Pochodne piperydyny, środki lecznicze zawierającepochodne piperydyny, sposoby wytwarzania tych pochodnych oraz zastosowanie pochodnych
CA2238081A1 (en) * 1995-11-22 1997-05-29 S. Jane Desolms Inhibitors of farnesyl-protein transferase
EP1009405A4 (en) 1997-08-28 2001-05-09 Merck & Co Inc PAYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
WO1999065867A1 (en) 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
US6274735B1 (en) * 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
AU747776B2 (en) 1998-10-30 2002-05-23 Merck & Co., Inc. Thrombin inhibitors
US6362201B1 (en) 1999-03-02 2002-03-26 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
US6303593B1 (en) 1999-03-02 2001-10-16 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
WO2000051610A1 (en) 1999-03-02 2000-09-08 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AU3818900A (en) 1999-04-14 2000-11-02 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
IL151552A0 (en) 2000-03-17 2003-04-10 Bristol Myers Squibb Pharma Co Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
JP2003529571A (ja) * 2000-04-04 2003-10-07 ブランデイス ユニヴァーシティー メソ形化合物の触媒的不斉非対称化
FR2811673B1 (fr) * 2000-07-17 2002-09-13 Rhodia Chimie Sa Utilisation de composes insatures comprenant un heterocycle comme stabilisants de polymeres halogenes
CA2425288A1 (en) 2000-10-11 2002-05-02 Sander G. Mills Pyrrolidine modulators of ccr5 chemokine receptor activity
WO2002076440A2 (en) 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
JP2004534017A (ja) 2001-04-27 2004-11-11 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｂａｃｅのインヒビター
AU2002341715A1 (en) 2001-09-17 2003-04-01 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
WO2003031443A1 (en) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
KR100783863B1 (ko) 2002-04-29 2007-12-10 액테리온 파마슈티칼 리미티드 7-아릴-3,9-디아자바이사이클로(3.3.1)논-6-엔 유도체 및고혈압, 심혈관 질환 또는 신장 질환의 치료에서 레닌저해물질로써 이들의 용도
ES2315568T3 (es) * 2002-05-20 2009-04-01 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido.
JP4579681B2 (ja) 2002-07-09 2010-11-10 ブリストル−マイヤーズ スクイブ カンパニー 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
US20040214832A1 (en) 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
US20060217371A1 (en) 2003-04-28 2006-09-28 Olivier Bezencon Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors
MXPA05011478A (es) 2003-04-29 2005-12-12 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,6-tetrahidropiridina 3,4-disustituidos novedosos.
CA2521938A1 (en) 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd 9-azabicyclo[3.3.1]non-6-ene derivatives with a heteroatom at the 3-position as renin inhibitors
MXPA05011496A (es) 2003-04-30 2005-12-15 Actelion Pharmaceuticals Ltd Derivados de azabiciclononeno.
MXPA05011497A (es) 2003-04-30 2005-12-15 Actelion Pharmaceuticals Ltd Derivados de tropano y su uso como inhibidores de la enzima de conversion de angiotensina (ace).
EP1622564A2 (en) 2003-05-02 2006-02-08 Actelion Pharmaceuticals Ltd. Diazabicyclononene derivatives
TW200513461A (en) * 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
CN1863773A (zh) 2003-10-09 2006-11-15 埃科特莱茵药品有限公司 四氢吡啶衍生物
DE602004022704D1 (de) 2003-11-26 2009-10-01 Novartis Ag 4-phenylpiperidinderivate als renininhibitoren
CA2600973C (en) 2003-11-26 2012-08-07 Novartis Ag .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid
BRPI0506490A (pt) 2004-01-23 2007-02-13 Speedel Experimenta Ag compostos orgánicos
DE602005025344D1 (de) 2004-01-23 2011-01-27 Novartis Ag Aminoalkoholderivate und deren wirkung als renininhibitoren
TW200535131A (en) 2004-01-23 2005-11-01 Speedel Experimenta Ag Organic compounds
WO2005090304A1 (en) 2004-03-19 2005-09-29 Speedel Experimenta Ag Organic compounds
EP1699762A1 (en) 2004-03-19 2006-09-13 Speedel Experimenta AG 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
TW200613274A (en) 2004-07-09 2006-05-01 Speedel Experimenta Ag Organic compounds
TW200631929A (en) 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
GB0428250D0 (en) 2004-12-23 2005-01-26 Novartis Ag Organic compounds
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0504850D0 (en) 2005-03-09 2005-04-13 Novartis Ag Organic compounds
BRPI0609158A2 (pt) 2005-03-11 2010-02-23 Speedel Experimenta Ag alcanamidas substituìdas heterocìclicas úteis como inibidores de renina
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
WO2006103275A1 (en) 2005-03-31 2006-10-05 Speedel Experimenta Ag 3,4,5-substituted piperidines as renin inhibitors
GB0508992D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
GB0510810D0 (en) 2005-05-26 2005-06-29 Novartis Ag Organic compounds
GB0511063D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
CN101268074B (zh) 2005-09-17 2011-09-21 斯皮德尔实验股份公司 5-氨基-4-羟基-7-（咪唑并[1,2-a]吡啶-6-基甲基）-8-甲基-壬酰胺衍生物和相关用作肾素抑制剂治疗高血压的化合物
AR057816A1 (es) 2005-09-17 2007-12-19 Speedel Experimenta Ag Compuestos organicos
PE20071079A1 (es) 2005-11-15 2007-12-16 Cytokinetics Inc Compuestos de piperidina como inhibidores de la proliferacion celular
JP5306821B2 (ja) 2005-12-30 2013-10-02 ノバルティス アーゲー レニン阻害剤としての３，５−置換ピペリジン化合物
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
CA2641120A1 (en) 2006-01-30 2007-08-02 Speedel Experimenta Ag Process for the stereoselective preparation of alcohols from alpha, beta- insaturated compounds
TW200815425A (en) 2006-06-08 2008-04-01 Speedel Experimenta Ag 2,5-disubstituted piperidines
GB0611696D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
GB0611697D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
EP1908471A1 (en) 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors

Also Published As

Publication number Publication date
PE20071177A1 (es) 2008-01-18
ES2476422T3 (es) 2014-07-14
PT2420491E (pt) 2013-10-14
CA2633624C (en) 2013-11-19
JP2009522226A (ja) 2009-06-11
AR058885A1 (es) 2008-02-27
EP2420491B1 (en) 2013-07-03
NO20083315L (no) 2008-09-19
PE20110117A1 (es) 2011-03-07
IL192024A0 (en) 2008-12-29
WO2007077005A1 (en) 2007-07-12
AU2006332124A1 (en) 2007-07-12
US20090192148A1 (en) 2009-07-30
EP1968940A1 (en) 2008-09-17
BRPI0620736A2 (pt) 2011-12-20
EP2420491A1 (en) 2012-02-22
AU2006332124B2 (en) 2011-03-03
ES2430139T3 (es) 2013-11-19
NZ569135A (en) 2011-08-26
MA30073B1 (fr) 2008-12-01
TW200738698A (en) 2007-10-16
JP5306821B2 (ja) 2013-10-02
ECSP088587A (es) 2008-07-30
CA2633624A1 (en) 2007-07-12
US8129411B2 (en) 2012-03-06
EP1968940B1 (en) 2014-04-02
KR20080086921A (ko) 2008-09-26
CR10091A (es) 2008-10-27

Similar Documents

Publication Publication Date Title
IL192024A0 (en) 3,5-substituted piperidine compounds as renin inhibitors
TWI369351B (en) 2,4-diamino-pyrimidines as aurora inhibitors
IL186130A0 (en) 3,4,5-substituted piperidines as renin inhibitors
PL1833816T3 (pl) Podstawione piperydyny jako inhibitory reniny
IL186124A0 (en) 3,4,5-substituted piperidines as renin inhibitors
IL180242A0 (en) Piperidine derivatives as renin inhibitors
IL186117A0 (en) Substituted piperidines as renin inhibitors
IL192053A0 (en) 2-adamantylurea derivatives as selective 11??-hsd1 inhibitors
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
ZA200804762B (en) 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors
IL191711A0 (en) 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors
ZA200804393B (en) Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors
EP1844003A4 (en) NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
ZA200810640B (en) 1,5 -Diphenylpyrazoles II as HSP90 Inhibitors
IL192227A0 (en) Amorphous form of 1,2-dihydropyridine compound
AP2007004171A0 (en) Novel compounds
EP1778693A4 (en) AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
EP1868612A4 (en) NOVEL CONNECTIONS
EP1868611A4 (en) NOVEL CONNECTIONS
IL187533A0 (en) Novel piperidine derivative
ZA200804956B (en) 3,5-substituted piperidine compounds as renin inhibitors
GB0500140D0 (en) Novel compounds
EP1869026A4 (en) NEW CONNECTIONS
HK1121445A (en) 3, 5-substitued piperidine compounds as renin inhibitors
HK1110311A (en) 3,4,5-substituted piperidines as renin inhibitors